Cellectis Employee Directory
Biotechnology ResearchÎle-de-france, France201-500 Employees
Cellectis is a global clinical-stage biotechnology company focused on developing cell and gene therapies using a genome editing platform. It concentrates on immuno-oncology and gene therapy by engineering allogeneic CAR-T cells designed to recognize and eliminate cancer cells. The firm is advancing two lead clinical programs for relapsed or refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma. It maintains end-to-end manufacturing control through a vertically integrated model, producing starting materials in Paris, Île-de-France, and finished CAR-T products in Raleigh, North Carolina. Headquartered in Paris, with additional sites in New York and Raleigh, the company collaborates with industry partners and is listed on Nasdaq and Euronext Growth. A notable recent development is that the FDA granted RMAT designation to lasme-cel, its CD22-targeting allogeneic CAR-T therapy, for relapsed or refractory B-cell ALL.
1-888-653-2347 
support@leadiq.com 
